<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429155</url>
  </required_header>
  <id_info>
    <org_study_id>6975</org_study_id>
    <nct_id>NCT01429155</nct_id>
  </id_info>
  <brief_title>Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B</brief_title>
  <official_title>Post Transplant Course of Hepatitis C Patients After Living Donor Liver Transplant in Association With Interleukin 28 B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a
      national organ shortage, living donor liver transplantation has became a viable option for
      patients with end stage liver disease who are not severely ill. Recently particular
      polymorphisms of IL-28B gene were reported to correlate with histological recurrence and
      antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar
      results have not been described yet in living donor liver transplant patients.

      There is data suggesting slightly inferior outcomes in living donor liver transplants when
      done for hepatitis C. The investigators postulate that such inferior outcomes may be related
      to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive
      similarly unfavorable polymorphism livers from their relatives).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response after living donor liver transplant</measure>
    <time_frame>12-24 months</time_frame>
    <description>Determine if sustained virological response is achieved after liver transplantation for hepatitis C with antiviral therapy (rivabirin and pegelated interferon) based on patient IL28B genotype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver retransplantation</measure>
    <time_frame>1-24 months</time_frame>
    <description>Determine the need of liver retransplantion based on the IL 28B genotype</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Liver transplant recipeints</arm_group_label>
    <description>Patients suffering from chronic hepatitis C that required a living donor liver transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver Donors</arm_group_label>
    <description>Patients who donated part of their liver to a patient suffering from chronic hepatitis C</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Interleukin 28B genotype</intervention_name>
    <description>Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)</description>
    <arm_group_label>Liver transplant recipeints</arm_group_label>
    <arm_group_label>Liver Donors</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C patients that required a living donor liver transplant will be
        identified from the liver tranplant registry.

        Living liver donors will be indentified from the liver tranplant registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received a living donor liver transplant for chronic hepatitis C who are
             18 year or older

          -  Patients who donated part of their liver to patients suffering from chronic hepatitis
             C. Donors must be 18 years or older

        Exclusion Criteria:

          -  Patients who are not willing to sign the consent

          -  Inability to obtain liver specimen (recipients)

          -  Inability to obtain blood sample (donors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Humberto C Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011 Jan;53(1):317-24. doi: 10.1002/hep.24074.</citation>
    <PMID>21254179</PMID>
  </reference>
  <reference>
    <citation>Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl. 2011 Mar;17(3):289-98. doi: 10.1002/lt.22235.</citation>
    <PMID>21384511</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2011</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Humberto C. Gonzalez</investigator_full_name>
    <investigator_title>Gastroenterology Fellow</investigator_title>
  </responsible_party>
  <keyword>End stage liver disease</keyword>
  <keyword>Living donor liver transplantation</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Interleukin 28B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

